Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB102 in severe to very severe alopecia areata
NCT07205159Phase 1Recruiting
- Sponsor
- Forte Biosciences, Inc.
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in alopecia areata comparing FB102 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events at 36 weeks and Change from Baseline of Severity of Alopecia Tool score at 16 weeks. Started Oct 2025; status: recruiting.
02
Drugs
FB102
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT07205159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07205159.